Trajan Wealth LLC Purchases 17,728 Shares of IQVIA Holdings Inc. $IQV

Trajan Wealth LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,541 shares of the medical research company’s stock after acquiring an additional 17,728 shares during the period. IQVIA makes up 1.2% of Trajan Wealth LLC’s portfolio, making the stock its 21st biggest holding. Trajan Wealth LLC’s holdings in IQVIA were worth $28,404,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Alliancebernstein L.P. grew its position in IQVIA by 0.6% during the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after buying an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA during the second quarter valued at approximately $515,772,000. JPMorgan Chase & Co. lifted its position in IQVIA by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after purchasing an additional 581,157 shares during the period. Nordea Investment Management AB boosted its stake in IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after buying an additional 253,759 shares in the last quarter. Finally, Cantillon Capital Management LLC raised its stake in shares of IQVIA by 27.3% in the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock valued at $366,002,000 after buying an additional 413,256 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $165.63 on Monday. The stock’s fifty day moving average is $217.61 and its 200-day moving average is $208.66. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The stock has a market capitalization of $28.11 billion, a PE ratio of 21.07, a PEG ratio of 1.60 and a beta of 1.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the prior year, the firm earned $3.12 EPS. The company’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IQV. Jefferies Financial Group lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Citigroup cut their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Finally, UBS Group dropped their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $235.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.